Mark Drummond Selected Research

Anemia

1/2018

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Drummond Research Topics

Disease

2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021 - 01/2016
2	Splenomegaly 10/2021 - 01/2018
2	Primary Myelofibrosis (Myelosclerosis) 10/2021 - 01/2018
1	Heart Failure 02/2024
1	Iron Overload 02/2024
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2024
1	Polycythemia Vera 01/2023
1	Hemorrhage 01/2023
1	Neoplasms (Cancer) 01/2023
1	Thrombosis (Thrombus) 01/2023
1	Wernicke Encephalopathy (Wernicke's Encephalopathy) 10/2021
1	Anemia 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Essential Thrombocythemia 01/2016
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2003

Drug/Important Bio-Agent (IBA)

2	ruxolitinibIBA 01/2023 - 01/2018
1	Chelating AgentsIBA 02/2024
1	Deferasirox FDA Link 02/2024
1	IronIBA 02/2024
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	fedratinibIBA 10/2021
1	Janus Kinase InhibitorsIBA 10/2021
1	Janus Kinase 2IBA 01/2018
1	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2018
1	Janus Kinase 1IBA 01/2018
1	RG7388IBA 01/2016
1	Proto-Oncogene Proteins c-mdm2IBA 01/2016
1	InterferonsIBA 01/2016
1	Imatinib Mesylate (Gleevec)FDA Link 08/2003

Therapy/Procedure

2	Therapeutics 01/2023 - 01/2018
1	Chelation Therapy (Therapy, Chelation) 02/2024
1	Drug Therapy (Chemotherapy) 10/2021